Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
VIEWPOINTS
PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the enrolment of the final patient in the (ECLIPSE) trial for SHIELD blood test to treat Colorectal CancerShots:The company has reported the patient enrolment in the (ECLIPSE) trial to evaluate SHIELD blood test in 12750 patients aged 45-84yr. with colorectal…
March 9, 20220Comments
PharmaShots Interview SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform
VIEWPOINTS
PharmaShots Interview: SalioGen Therapeutics’ Ray Tabibiazar Shares Insights on Gene Coding Platform
In an interview with PharmaShots, Ray Tabibiazar, M.D., Chief Executive Officer and Chairman, Board of Directors at SalioGen Therapeutics shares his views on the completion of $115M series B financing to advance gene coding platform for genetic diseasesShots:The company has completed $115M series B financing which was co-led by GordonMD global investments and EPIQ capital group. The financing will…
March 8, 20220Comments
ThoughtSpot_Senior Editor
THOUGHTSPOT
How Pharma 4.0 Influences Cell and Gene Therapy
Pharma 4.0 foresees a manufacturing environment that is mostly automated and barely depends on human labor. Production systems would be interconnected with each other, as well as with supply chain management systems and quality assessment systems, all orchestrated by machine-learning-driven AI control systems. As such, smart factories promise higher productivity, better quality, and enhanced agility.…
March 7, 20220Comments
Insights+ Key Biosimilars Events of February 2022
INSIGHTS+
Insights+ Key Biosimilars Events of February 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of February, Biocon acquired Viatris’ biosimilars assets for ~$3.335B,…
March 3, 20220Comments
VIEWPOINTS
PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials
In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseasesShots:Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…
March 1, 20220Comments
PharmaShots Interview Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
VIEWPOINTS
PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
In an interview with PharmaShots, Jonathan Wang, Executive Vice President and Head of Business Development at Zai Lab shares his views on the license agreement with Karuna Therapeutics for KarXT (xanomeline-trospium) to treat schizophrenia and psychosisShots:The companies collaborate to develop, manufacture & commercialize KarXT in Greater China including mainland China, Hong Kong, Macau & TaiwanZai Lab gets exclusive rights to develop &…
February 28, 20220Comments
Viewpoints_Senior Editor
VIEWPOINTS
PharmaShots Interview: Boston Scientific’s Ron Morton Shares Insights on the Rezūm Water Vapor Therapy
In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on Rezūm Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasiaShots:The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
February 24, 20220Comments
Viewpoints_Tania Small
VIEWPOINTS
PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program
In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma communityShots:The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the communityA grant of…
February 23, 20220Comments